Abstract |
Amonafide demonstrated a poor response rate and substantial toxicity in patients who had measurable, advanced mixed mesodermal tumors of the uterus. Amonafide-a drug that acts through intercalation of tumor DNA-was used to treat 16 patients who had measurable, advanced mixed mesodermal tumors of the uterus as part of a Gynecologic Oncology Group (GOG) Phase II study. The starting dose was 300 mg/m2 intravenously over 1 hour for 5 consecutive days every 3 weeks. Severe or life-threatening hematologic toxicity occurred in 50% of the patients. Two patients experienced vomiting requiring hospitalization. Other toxicities were not severe. One patient had a partial response and one had stable disease, each lasting 4 months. This dose schedule was associated with poor response rate and substantial toxicity.
|
Authors | R Asbury, J A Blessing, E Podczaski, H Ball |
Journal | American journal of clinical oncology
(Am J Clin Oncol)
Vol. 21
Issue 3
Pg. 306-7
(Jun 1998)
ISSN: 0277-3732 [Print] United States |
PMID | 9626805
(Publication Type: Clinical Trial, Clinical Trial, Phase II, Journal Article, Research Support, U.S. Gov't, P.H.S.)
|
Chemical References |
- Antineoplastic Agents
- Imides
- Isoquinolines
- Naphthalimides
- Organophosphonates
- amonafide
- Adenine
|
Topics |
- Adenine
- Adult
- Aged
- Aged, 80 and over
- Antineoplastic Agents
(adverse effects, therapeutic use)
- Female
- Humans
- Imides
(adverse effects, therapeutic use)
- Isoquinolines
(adverse effects, therapeutic use)
- Leukopenia
(chemically induced)
- Middle Aged
- Mixed Tumor, Mesodermal
(drug therapy)
- Naphthalimides
- Organophosphonates
- Thrombocytopenia
(chemically induced)
- Uterine Neoplasms
(drug therapy)
|